Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology is a late-stage clinical biopharmaceutical company with a promising product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company has a strong pipeline and upcoming catalysts, including a potential BLA filing in 2026 and data updates for multiple clinical trials. While the financials show increasing spend, the company has a strong cash position to support its operations through 2029. Risks to achieving their price target include potential clinical failures and challenges in gaining regulatory approval and commercializing their products, but their early data has shown compelling activity and a clean safety profile.

Bears say

CG Oncology is a late-stage biopharmaceutical company with a negative outlook due to the competitive landscape and potential limitations in their product candidate. Despite potential catalysts such as upcoming Phase 3 data and BLA filing, the company faces challenges in differentiating itself in the market and addressing questions around durability, schedule preference, and competitive positioning. The ongoing global BCG shortage may provide some opportunities, but the company's potential peak revenues of $3B in 2034 are lower compared to other competitors in the same space.

CGON has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 8 analysts, CGON has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.